Associations Between HDL Particles and Ischemic Events by Vascular Domain, Gender, and Ethnicity: A Pooled Cohort Analysis

HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population

(2019) Sanam Ebtehaj et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

(2019) Fabian J Brunner et al.   LANCET

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial

(2018) James D. Otvos et al.   Journal of Clinical Lipidology

Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque

(2018) Steven Shea et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

(2017) A. Michael Lincoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study)

(2015) Alvin Chandra et al.   AMERICAN JOURNAL OF CARDIOLOGY

HDL particle number measured on the Vantera®, the first clinical NMR analyzer

(2015) Steven P. Matyus et al.   CLINICAL BIOCHEMISTRY

Cholesterol-Overloaded HDL Particles Are Independently Associated With Progression of Carotid Atherosclerosis in a Cardiovascular Disease-Free Population

(2015) Yue Qi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy

(2013) Samia Mora et al.   CIRCULATION

Albuminuria, Estimated GFR, Traditional Risk Factors, and Incident Cardiovascular Disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) Study

(2012) Paul A. Smink et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study

(2012) Sarah Parish et al.   CIRCULATION

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: The Atherosclerosis Risk in Communities (ARIC) carotid MRI study

(2011) Salim S. Virani et al.   ATHEROSCLEROSIS

Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects

(2011) Salim S. Virani et al.   CIRCULATION

The surprising AIM-HIGH results are not surprising when viewed through a particle lens

(2011) James D. Otvos   Journal of Clinical Lipidology

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number

(2011) James D. Otvos et al.   Journal of Clinical Lipidology

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein

(2010) P. J. W. H. Kappelle et al.   JOURNAL OF INTERNAL MEDICINE

Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD

(2008) Haseeb Jafri et al.   Journal of Clinical Lipidology

High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

(2008) Wim A. van der Steeg et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: A systematic review

(2007) Pierre Amarenco et al.   ATHEROSCLEROSIS